Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 8/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006598 | 0.78 | PTGDR2 (0.48) | PLA2G1BPTGDR2PTGDRKMT2AMEN1 | |
| SCHEMBL7013826 | 0.72 | PTGDR2 (0.48) | PLA2G1BPTGDR2PTGDRPLA2G2AALDH1A1 | |
| SCHEMBL7009318 | 0.72 | PTGDR (0.42) | PLA2G1BPTGDR2PTGDRKMT2AMEN1 | |
| SCHEMBL27159577 | 0.71 | PTGDR2 (0.61) | PTGDR2PTGDRKMT2AMEN1ALDH1A1 | |
| SCHEMBL7014306 | 0.70 | PLA2G1B (0.61) | PLA2G1BPTGDR2PTGDRPLA2G2AALDH1A1 | |
| SCHEMBL9080973 | 0.67 | KMT2A (0.41) | KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL7010673 | 0.66 | PLA2G1B (1.00) | PLA2G1B | |
| SCHEMBL7012342 | 0.65 | LMNA (0.46) | PLA2G1BKMT2AMEN1PLA2G2AALDH1A1 | |
| SCHEMBL7006844 | 0.65 | PLA2G1B (0.98) | PLA2G1B | |
| SCHEMBL7006564 | 0.63 | LMNA (0.43) | PLA2G1BKMT2AMEN1PLA2G2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |